EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Partnerships
Genetic Technologies and Stayhealthy partner to distribute Multi-Risk Test in North America
Precision Medicine
Jun 5, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Product updates
Partnerships
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Precision Medicine

Precision Medicine

Jun 5, 2024

Genetic Technologies and Stayhealthy partner to distribute Multi-Risk Test in North America

Partnerships

  • Genetic Technologies has collaborated with Stayhealthy to promote the use of the Multi-Risk Test on a wider scale across North America's online pharmacy channel.

  • The collaboration will allow Genetic Technologies to distribute its Multi-Risk Test through Stayhealthy's online platform, StayHealthyRx, expanding the accessibility of personalized health risk assessments. This partnership is expected to give users extensive insights into health risks and advise on practical actions to alleviate them.

  • Genetic Technologies is a molecular diagnostics company based in Australia, specializing in predictive genetic testing and risk assessment tools. The company operates in the market through its brands AffinityDNA, EasyDNA, and GeneType. Its key product is the GeneType Multi Test, a combination of geneType tests for breast, colorectal, ovarian, and prostate cancer, as well as coronary artery disease and type 2 diabetes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.